Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 3/20 | 0.46 |
| ▸ | CPT1A | P50416 | 3/20 | 0.46 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.46 |
| ▸ | CRAT | P43155 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3688621 | 1.00 | CPT2 (0.46) | CPT2CPT1ACPT1BCRATMEN1 | |
| SCHEMBL13410007 | 0.91 | MEN1 (0.44) | MEN1MAPTKMT2ASAE1UBA2 | |
| SCHEMBL3680702 | 0.83 | CPT2 (0.52) | CPT2CPT1ACPT1BCRATMEN1 | |
| SCHEMBL3680697 | 0.83 | CPT2 (0.52) | CPT2CPT1ACPT1BCRATMEN1 | |
| SCHEMBL20657450 | 0.82 | KMT2A (0.45) | CPT2CPT1ACPT1BCRATMEN1 | |
| SCHEMBL3690729 | 0.82 | KMT2A (0.45) | CPT2CPT1ACPT1BCRATMEN1 | |
| SCHEMBL3693612 | 0.79 | CPT2 (0.45) | CPT2CPT1ACPT1BCRATMAPT | |
| SCHEMBL3693608 | 0.79 | CPT2 (0.45) | CPT2CPT1ACPT1BCRATMAPT | |
| SCHEMBL3689478 | 0.77 | MAPK1 (0.56) | CPT2CPT1ACPT1BCRATCA12 | |
| SCHEMBL3689475 | 0.77 | MAPK1 (0.56) | CPT2CPT1ACPT1BCRATCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | CPT2 3/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.